All‐cause mortality · patients with cancer with venous thromboembolism
Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).
1 finding from 1 review
All‐cause mortality · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in mortality compared with inpatients ‐ adults (moderate certainty).
1 finding from 1 review
All‐cause mortality · Children with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in mortality compared with inpatients ‐ children (moderate certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All cause‐mortality · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Cancer mortality risk No. of participants: 17,448 (1 RCT) · Participants in trials with low risk of bias
Highest showed no clear difference in cancer mortality risk No. of participants: 17,448 (1 RCT) compared with lowest selenium exposure (high certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Mortality: all cancers · adults (aged at least 18 years)
Highest showed no clear difference in any cancer mortality (8 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.99 [0.91, 1.07]
504366 participants
Low
All cause mortality · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics leads to lower all cause mortality compared with placebo or no intervention (high certainty).
1 finding from 1 review
Mortality: all cancers · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes cancer mortality risk No. of participants: 183,863 (7 observational… compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · people with non‐rhabdomyosarcoma soft tissue sarcoma
1 finding from 1 review